212 related articles for article (PubMed ID: 8535858)
1. Effects of chronic naloxone administration on vacuous chewing movements and catalepsy in rats treated with long-term haloperidol decanoate.
Egan MF; Ferguson JN; Hyde TM
Brain Res Bull; 1995; 38(4):355-63. PubMed ID: 8535858
[TBL] [Abstract][Full Text] [Related]
2. Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate.
Hyde TM; Egan MF; Wing LL; Wyatt RJ; Weinberger DR; Kleinman JE
Psychopharmacology (Berl); 1995 Mar; 118(2):142-9. PubMed ID: 7617800
[TBL] [Abstract][Full Text] [Related]
3. Haloperidol versus risperidone on rat "early onset" vacuous chewing.
Marchese G; Bartholini F; Casu MA; Ruiu S; Casti P; Congeddu E; Tambaro S; Pani L
Behav Brain Res; 2004 Feb; 149(1):9-16. PubMed ID: 14739005
[TBL] [Abstract][Full Text] [Related]
4. Neuroleptic-induced vacuous chewing movements in rodents: incidence and effects of long-term increases in haloperidol dose.
Egan MF; Hyde TM; Kleinman JE; Wyatt RJ
Psychopharmacology (Berl); 1995 Jan; 117(1):74-81. PubMed ID: 7724705
[TBL] [Abstract][Full Text] [Related]
5. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements.
Naidu PS; Kulkarni SK
Eur J Pharmacol; 2001 Sep; 428(1):81-6. PubMed ID: 11779040
[TBL] [Abstract][Full Text] [Related]
6. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats.
Haleem DJ; Samad N; Haleem MA
Pharmacol Biochem Behav; 2007 May; 87(1):115-21. PubMed ID: 17498786
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol.
Egan MF; Hurd Y; Ferguson J; Bachus SE; Hamid EH; Hyde TM
Psychopharmacology (Berl); 1996 Oct; 127(4):337-45. PubMed ID: 8923569
[TBL] [Abstract][Full Text] [Related]
8. Oral Dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid.
Andreassen OA; Ferrante RJ; Beal MF; Jørgensen HA
Neuroscience; 1998 Dec; 87(3):639-48. PubMed ID: 9758230
[TBL] [Abstract][Full Text] [Related]
9. GM1 ganglioside attenuates the development of vacuous chewing movements induced by long-term haloperidol treatment of rats.
Andreassen OA; Jørgensen HA
Psychopharmacology (Berl); 1994 Dec; 116(4):517-22. PubMed ID: 7701057
[TBL] [Abstract][Full Text] [Related]
10. The relationship between motor effects in rats following acute and chronic haloperidol treatment.
Jørgensen HA; Andreassen OA; Hole K
Psychopharmacology (Berl); 1994 Sep; 116(1):89-92. PubMed ID: 7862936
[TBL] [Abstract][Full Text] [Related]
11. Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide.
Naidu PS; Kulkarni SK
Behav Pharmacol; 2001 Jun; 12(3):209-16. PubMed ID: 11485057
[TBL] [Abstract][Full Text] [Related]
12. Relationship of orofacial movements to behavioural repertoire as assessed topographically over the course of 6-month haloperidol treatment followed by 4-month withdrawal.
De Souza IE; Dawson NM; Clifford JJ; Waddington JL; Meredith GE
Psychopharmacology (Berl); 2003 Aug; 169(1):28-34. PubMed ID: 12830366
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of hesperetin against haloperidol-induced orofacial dyskinesia and catalepsy in rats.
Dhingra D; Goswami S; Gahalain N
Nutr Neurosci; 2018 Nov; 21(9):667-675. PubMed ID: 28641484
[TBL] [Abstract][Full Text] [Related]
14. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats.
Turrone P; Remington G; Kapur S; Nobrega JN
Psychopharmacology (Berl); 2003 Jan; 165(2):166-71. PubMed ID: 12417967
[TBL] [Abstract][Full Text] [Related]
15. Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains.
Tamminga CA; Dale JM; Goodman L; Kaneda H; Kaneda N
Psychopharmacology (Berl); 1990; 102(4):474-8. PubMed ID: 1982902
[TBL] [Abstract][Full Text] [Related]
16. Blockade of nigral and pallidal opioid receptors suppresses vacuous chewing movements in a rodent model of tardive dyskinesia.
McCormick SE; Stoessl AJ
Neuroscience; 2002; 112(4):851-9. PubMed ID: 12088744
[TBL] [Abstract][Full Text] [Related]
17. Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats.
Bordia T; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2012 Mar; 340(3):612-9. PubMed ID: 22144565
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
Bishnoi M; Chopra K; Kulkarni SK
Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of antipsychotics on haloperidol-induced vacuous chewing movements and subcortical gene expression in the rat.
McCullumsmith RE; Stincic TL; Agrawal SM; Meador-Woodruff JH
Eur J Pharmacol; 2003 Sep; 477(2):101-12. PubMed ID: 14519413
[TBL] [Abstract][Full Text] [Related]
20. Difference in catalepsy response in inbred rats during chronic haloperidol treatment is not predictive of the intensity of behavioral hypersensitivity which subsequently develops.
Kinon BJ; Kane JM
Psychopharmacology (Berl); 1989; 98(4):465-71. PubMed ID: 2505286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
